In the present study, we have developed a strategy to address some limitations of anti-CD19/CD3 BiTE by establishing a novel OV-BiTE using an oncolytic vaccinia virus that encodes within it a CD19-specific BiTE for secretion by infected B-cell lymphoma cells. This evidence concerns the gene CD19 and B-cell non-Hodgkin lymphoma.